MapLight Therapeutics (MPLT) Research & Development (2024 - 2025)
MapLight Therapeutics (MPLT) reported Research & Development of $64.6 million for Q4 2025, up 211.99% on a YoY basis from $20.7 million in Q4 2024, and up 138.51% sequentially from $27.1 million in Q3 2025.
MapLight Therapeutics (MPLT) Research & Development (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Research & Development data on file, last reported at $64.6 million in Q4 2025.
- For the quarter ending Q4 2025, Research & Development rose 211.99% year-over-year to $64.6 million; the trailing twelve-month figure through Dec 2025 stood at $129.2 million (changed N/A YoY), and the FY2025 full-year result was $138.3 million, up 101.9% from the prior year.
- Research & Development advanced to $64.6 million in Q4 2025, from $27.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $64.6 million in Q4 2025 to a low of $16.8 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | MapLight Therapeutics | 314.07 Mn | 314.07 Mn | - | 64.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 64.62 Mn |
| Sep 30, 2025 | 27.09 Mn |
| Dec 31, 2024 | 20.71 Mn |
| Sep 30, 2024 | 16.81 Mn |